La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

NATCO Pharma Croissance future

Future contrôle des critères 1/6

Les bénéfices de NATCO Pharma devraient diminuer de 8.7% par an tandis que son chiffre d'affaires annuel devrait croître de 1.9% par an. Le BPA devrait croître de diminuer de 8.7% par an. Le rendement des capitaux propres devrait être 20.9% dans 3 ans.

Informations clés

-8.7%

Taux de croissance des bénéfices

-8.7%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices	17.6%
Taux de croissance des recettes	1.9%
Rendement futur des capitaux propres	20.9%
Couverture par les analystes	Good
Dernière mise à jour	14 Aug 2024

Mises à jour récentes de la croissance future

NATCO Pharma Limited (NSE:NATCOPHARM) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models

May 30

Recent updates

NATCO Pharma Limited's (NSE:NATCOPHARM) Shares Bounce 26% But Its Business Still Trails The Market

Aug 13

If EPS Growth Is Important To You, NATCO Pharma (NSE:NATCOPHARM) Presents An Opportunity

Jul 15

NATCO Pharma (NSE:NATCOPHARM) Seems To Use Debt Rather Sparingly

Jun 30

NATCO Pharma Limited's (NSE:NATCOPHARM) Earnings Are Not Doing Enough For Some Investors

Jun 14

NATCO Pharma Limited (NSE:NATCOPHARM) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models

May 30

NATCO Pharma Limited Just Beat EPS By 223%: Here's What Analysts Think Will Happen Next

Feb 18

NATCO Pharma Limited (NSE:NATCOPHARM) Surges 25% Yet Its Low P/E Is No Reason For Excitement

Feb 17

Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?

Jan 25

An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 37% Undervalued

Jan 09

Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?

Dec 13

An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 42% Undervalued

Sep 30

Here's Why We Think NATCO Pharma (NSE:NATCOPHARM) Might Deserve Your Attention Today

Sep 12

NATCO Pharma (NSE:NATCOPHARM) Is Paying Out A Larger Dividend Than Last Year

Aug 12

Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?

Jul 16

NATCO Pharma Limited (NSE:NATCOPHARM) Shares Could Be 44% Below Their Intrinsic Value Estimate

Apr 20

Is NATCO Pharma Limited (NSE:NATCOPHARM) Trading At A 46% Discount?

Dec 20

NATCO Pharma's (NSE:NATCOPHARM) Upcoming Dividend Will Be Larger Than Last Year's

Aug 12

Does NATCO Pharma (NSE:NATCOPHARM) Have A Healthy Balance Sheet?

Jun 23

Broker Revenue Forecasts For NATCO Pharma Limited (NSE:NATCOPHARM) Are Surging Higher

Jun 02

NATCO Pharma's (NSE:NATCOPHARM) Shareholders Will Receive A Bigger Dividend Than Last Year

Feb 22

Estimating The Intrinsic Value Of NATCO Pharma Limited (NSE:NATCOPHARM)

Feb 16

Prévisions de croissance des bénéfices et des revenus

NSEI:NATCOPHARM - Estimations futures des analystes et données financières antérieures (INR Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
3/31/2027	36,606	8,059	8,293	N/A	4
3/31/2026	55,261	20,104	16,607	N/A	11
3/31/2025	49,786	19,699	11,295	N/A	9
6/30/2024	43,490	16,365	N/A	N/A	N/A
3/31/2024	41,269	13,883	8,529	12,116	N/A
12/31/2023	38,298	12,778	N/A	N/A	N/A
9/30/2023	35,637	11,274	5,230	7,477	N/A
6/30/2023	29,630	8,152	N/A	N/A	N/A
3/31/2023	27,085	7,153	6,435	8,491	N/A
12/31/2022	24,074	3,890	N/A	N/A	N/A
9/30/2022	24,754	4,071	5,575	8,302	N/A
6/30/2022	24,191	4,154	N/A	N/A	N/A
3/31/2022	19,462	1,700	-1,962	465	N/A
12/31/2021	16,833	2,735	N/A	N/A	N/A
9/30/2021	14,780	2,558	-2,457	230	N/A
6/30/2021	18,990	3,931	N/A	N/A	N/A
3/31/2021	20,561	4,409	465	2,988	N/A
12/31/2020	21,756	4,820	N/A	N/A	N/A
9/30/2020	23,026	5,238	1,554	4,466	N/A
6/30/2020	19,861	4,404	N/A	N/A	N/A
3/31/2020	19,150	4,608	587	4,173	N/A
12/31/2019	19,159	4,875	N/A	N/A	N/A
9/30/2019	19,904	5,425	-2,200	1,600	N/A
6/30/2019	20,482	6,060	N/A	N/A	N/A
3/31/2019	20,945	6,444	2,071	6,688	N/A
12/31/2018	24,066	8,235	N/A	N/A	N/A
9/30/2018	24,121	8,815	N/A	N/A	N/A
6/30/2018	22,953	7,838	N/A	N/A	N/A
3/31/2018	21,848	6,962	N/A	4,636	N/A
12/31/2017	19,817	5,730	N/A	N/A	N/A
9/30/2017	20,895	5,506	N/A	4,985	N/A
6/30/2017	21,679	5,323	N/A	N/A	N/A
3/31/2017	20,202	4,860	N/A	3,458	N/A
12/31/2016	17,697	3,680	N/A	N/A	N/A
9/30/2016	13,692	2,113	N/A	N/A	N/A
6/30/2016	12,431	1,748	N/A	N/A	N/A
3/31/2016	10,423	1,549	N/A	1,122	N/A
12/31/2015	9,355	1,494	N/A	N/A	N/A
9/30/2015	8,549	1,266	N/A	N/A	N/A
6/30/2015	8,390	1,294	N/A	N/A	N/A
3/31/2015	7,305	1,293	N/A	927	N/A
12/31/2014	8,089	1,042	N/A	N/A	N/A
9/30/2014	8,108	1,199	N/A	N/A	N/A
6/30/2014	7,648	1,144	N/A	N/A	N/A
3/31/2014	7,389	1,027	N/A	1,440	N/A
12/31/2013	7,078	900	N/A	N/A	N/A
9/30/2013	6,796	826	N/A	N/A	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: Les bénéfices de NATCOPHARM devraient diminuer au cours des 3 prochaines années ( -8.7% par an).

Bénéfices vs marché: Les bénéfices de NATCOPHARM devraient diminuer au cours des 3 prochaines années ( -8.7% par an).

Croissance élevée des bénéfices: Les bénéfices de NATCOPHARM devraient baisser au cours des trois prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de NATCOPHARM ( 1.9% par an) devrait croître plus lentement que le marché de Indian ( 10% par an).

Croissance élevée des revenus: Le chiffre d'affaires de NATCOPHARM ( 1.9% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de NATCOPHARM devrait être élevé dans 3 ans ( 20.9 %)

NATCO Pharma Croissance future

Future contrôle des critères 1/6

Informations clés

Mises à jour récentes de la croissance future

Consensus EPS estimates increase by 14%

Price target increased by 11% to ₹1,180

Consensus EPS estimates increase by 14%

Price target increased by 9.1% to ₹1,064

NATCO Pharma Limited (NSE:NATCOPHARM) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models

Consensus EPS estimates increase by 17%

Recent updates

Consensus EPS estimates increase by 14%

Price target increased by 11% to ₹1,180

NATCO Pharma Limited Declares Interim Dividend for the Financial Year 2024-25, Payable from August 30, 2024

Dividend of ₹3.00 announced

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

NATCO Pharma Limited's (NSE:NATCOPHARM) Shares Bounce 26% But Its Business Still Trails The Market

NATCO Pharma Limited Announces Term Completion of Directors

NATCO Pharma Limited, Annual General Meeting, Sep 30, 2024

NATCO Pharma Limited Announces Resignation of Sanivarapu Ravi Prakash Reddy as Senior Vice President - Operations

NATCO Pharma Limited to Report Q1, 2025 Results on Aug 12, 2024

If EPS Growth Is Important To You, NATCO Pharma (NSE:NATCOPHARM) Presents An Opportunity

NATCO Pharma (NSE:NATCOPHARM) Seems To Use Debt Rather Sparingly

Board Member recently sold ₹6.0m worth of stock

NATCO Pharma Limited's (NSE:NATCOPHARM) Earnings Are Not Doing Enough For Some Investors

Investor sentiment improves as stock rises 21%

Consensus EPS estimates increase by 14%

Price target increased by 9.1% to ₹1,064

NATCO Pharma Limited (NSE:NATCOPHARM) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models

New major risk - Revenue and earnings growth

Full year 2024 earnings: EPS and revenues exceed analyst expectations

NATCO Pharma Limited to Report Q4, 2024 Results on May 27, 2024

Calculating The Fair Value Of NATCO Pharma Limited (NSE:NATCOPHARM)

Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?

Now 22% undervalued

Now 20% undervalued

Consensus EPS estimates increase by 17%

Investor sentiment improves as stock rises 16%

NATCO Pharma (NSE:NATCOPHARM) Is Due To Pay A Dividend Of ₹1.25

Upcoming dividend of ₹1.25 per share

NATCO Pharma Limited Just Beat EPS By 223%: Here's What Analysts Think Will Happen Next

NATCO Pharma Limited (NSE:NATCOPHARM) Surges 25% Yet Its Low P/E Is No Reason For Excitement

Price target increased by 8.9% to ₹895

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Corporate Action-Board Approves Third Interim Dividend for the Financial Year 2023-24, Payable on 4 March 2024

NATCO Pharma Limited to Report Q3, 2024 Results on Feb 14, 2024

Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?

An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 37% Undervalued

Board Member recently sold ₹8.0m worth of stock

Insider recently sold ₹1.2m worth of stock

Board Member recently sold ₹7.9m worth of stock

Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?

Insider recently sold ₹1.6m worth of stock

NATCO Pharma Limited Declares Second Interim Dividend for the Financial Year 2023-24, Payable on 1 December, 2023

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

NATCO Pharma Limited to Report Q2, 2024 Results on Nov 14, 2023

An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 42% Undervalued

Here's Why We Think NATCO Pharma (NSE:NATCOPHARM) Might Deserve Your Attention Today

NATCO Pharma Limited, Annual General Meeting, Sep 29, 2023

Upcoming dividend of ₹7.00 per share at 0.7% yield

NATCO Pharma (NSE:NATCOPHARM) Is Paying Out A Larger Dividend Than Last Year

Price target increased by 9.6% to ₹734

NATCO Pharma Limited Declares Interim Dividend for the Financial Year 2023-24

First quarter 2024 earnings: EPS exceeds analyst expectations

NATCO Pharma Limited to Report Q1, 2024 Results on Aug 09, 2023

Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?

NATCO Pharma Limited (NSEI:NATCOPHARM) agreed to acquire Zista Pharma Limited for $3 million.

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

NATCO Pharma Limited (NSE:NATCOPHARM) Shares Could Be 44% Below Their Intrinsic Value Estimate

Insider recently bought ₹161k worth of stock

NATCO Pharma Limited Files Generic Olaparib Tablets in USA

Upcoming dividend of ₹1.25 per share at 1.2% yield

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

NATCO Pharma Limited Approves Third Interim Dividend for the Financial Year 2022-23, Payable on March 1, 2023

NATCO Pharma Limited to Report Q3, 2023 Results on Feb 09, 2023

MD & Director recently bought ₹5.0m worth of stock

Is NATCO Pharma Limited (NSE:NATCOPHARM) Trading At A 46% Discount?

Natco Pharma Limited Announces Double Bench of the High Court of Delhi Dismiss an Appeal Filed by FMC Corporation, FMC Singapore and FMC India

Price target decreased to ₹709

Consensus EPS estimates fall by 10%